For the experimental design of improving human memory ability through genetic engineering, it is necessary to take into account scientific rigor, ethics and technical feasibility. The following is a phased experimental framework： ###1. Basic research stage 1. **Target gene screening** - Focus on neuroplasticity-related genes (NR2B, CREB, BDNF) -Analysis of gene expression regulatory networks (miRNA regulatory mechanisms) -Establish a gene interaction model to predict synergistic effects 2. **In vitro model construction** -3D neural organoid culture (using iPSC technology) -Microfluidic chip simulates the blood-brain barrier -Optogenetic technology monitors changes in synaptic plasticity in real time ### 2. Animal experiment stage 1. **Gene editing system optimization** -Development of spatiotemporal-specific CRISPR-Cas9 delivery system -Test new base editing technology (ABE/CBE) -Establish a conditional gene activation/inhibition model 2. **Behavioral verification** -Improved version of Morris Water Maze (added multimodal stimulation) -Social memory test (homologous mouse recognition) -A new type of memory consolidation paradigm (repetitive learning at intervals) ###3. Translational Medicine Research 1. **Safety assessment system** -Genome-wide off-target effect detection -Dynamic monitoring of neuroinflammatory response -Tracking of cross-generational genetic effects (three-generation animal model) 2. **Cognitive enhancement quantification** -fMRI brain network connection analysis -Single-cell transcriptome sequencing -Real-time monitoring of neurotransmitter release technology ###4. Ethical and technical challenges 1. **Risk control mechanism** -Double-lock gene switch design (small molecule induction system) -Development of reversible editing technology -Region-specific expression control (hippocampus targeting) 2. **Social impact assessment** -Cognitive enhancement fairness model -Simulation of side effects of memory enhancement (risk of information overload) -Neurodiversity protection program ###5. Expectations of phased results 1. Short-term (3-5 years)： -Establish a memory enhancement model for non-human primates -Develop safety assessment standards for memory-related gene editing 2. Medium term (5-10 years)： -Completed the first out-of-body human neural network enhancement experiment -Build an AI model of memory-enhanced risk prediction 3. Long-term (more than 10 years)： -Development of controllable gene therapy vectors -Establish a neural enhancement ethical decision-making framework The experimental design emphasizes a progressive verification system, and terminable nodes are set up at each stage to ensure that the research risks are controllable. The key innovation point lies in the combination of optogenetic monitoring and gene editing technology to realize real-time visual verification of the memory coding process. At the same time, it is recommended to adopt an "enhancement-inhibition" dual-mode system to provide emergency intervention for possible side effects.